Brotizolam

Brotizolam is a sedative-hypnotic of the thienotriazolodiazepine class, a benzodiazepine analog patented in 1974 and introduced into medical use in 1984. It is prescribed for short-term treatment of severe insomnia in parts of Europe, Israel, and Japan. Brotizolam is notable for its exceptional potency and rapid elimination, producing effects comparable to triazolam and midazolam. As with other benzodiazepines, it carries risks of respiratory depression when combined with other depressants, as well as amnesia and habit formation.

Also known as: Dormex, Noxtal, We-941, Lendorm, Goodmin, Lendormin, Mederantil, Nimbisan, Sintonal, WE-941-BS

Classification

Chemical: Benzodiazepine
Chemical: Medicine
Psychoactive: Depressant
Tag: Anxiolytic
Tag: Habit-Forming
Tag: Sedative
Tag: Thienotriazolodiazepine

Effects

Sedation
Muscle Relaxation
Headache
Nausea
Respiratory Depression
Abnormal Heartbeat
Anxiety
Anxiety Suppression
Amnesia
Confusion
Cognitive Fatigue
Dizziness
External Hallucination
Dulled Perception
Disinhibition
Blurred Vision
Decreased Libido
Environmental Transfiguration

Routes of Administration

Oral

Dosage

Heavy: 600 ug
Light: 100-200 ug
Common: 200 – 400 µg
Strong: 400-600 ug
Threshold: 100 ug

Duration

After Effects: 6-12 h
Onset: 0.25-0.5 h
Peak: 1-2 h
Offset: 4-6 h
Total Duration: 6-8 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu